What Is the Clinical Course of Advanced Liver Disease and What Symptoms Are Associated With It?

Evidence-Based Practice of Palliative Medicine

Volumn , Issue , 2012, Pages 300-307

  Hope, Aluko A ^a,b   Morrison, R Sean ^c,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Jay B Langer Critical Care System   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901896304     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-3796-7.00053-7     Document Type: Chapter

References (64)

1. Larson A.M., Curtis J.R. Integrating palliative care for liver transplant candidates: "too well for transplant, too sick for life". JAMA. 2006, 295:2168-2176.
2. Murphy S.L., Xu J., Kochanek K.D. Deaths: preliminary data for 2010. Nat Vital Stat Rep. 2012, 60:7.
3. The U.S.Organ Procurement and Transplantation Network, Scientific Registry of Transplant Recipients OPTN/SRTR 2010 Annual Data Report 2011, Rockville, MD.
4. Fox E., Landrum-McNiff K., Zhong Z., Dawson N.V., Wu A.W., Lynn J. Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. SUPPORT Investigators: Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. JAMA 1999, 282:1638-1645.
5. Guy V. Liver failure, life support, family support, and palliation: an inside story. J Crit Care. 2006, 21:250-252.
6. Bajaj J.S. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol. 2008, 14:3609-3615.
7. Schomerus H., Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis. 2001, 16:37-41.
8. Bell B.P., Manos M.M., Zaman A., et al. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am J Gastroenterol. 2008, 103:2727-2736. quiz 37.
9. Basra G., Basra S., Parupudi S. Symptoms and signs of acute alcoholic hepatitis. World J Hepatol. 2011, 3:118-120.
10. Basra S., Anand B.S. Definition, epidemiology and magnitude of alcoholic hepatitis. World J Hepatol. 2011, 3:108-113.
11. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007, 132:2557-2576.
12. Parikh S., Hyman D. Hepatocellular cancer: a guide for the internist. Am J Med. 2007, 120:194-202.
13. Cahill B.A., Braccia D. Current treatment for hepatocellular carcinoma. Clin J Oncol Nurs. 2004, 8:393-399.
14. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996, 334:693-699.
15. Roth K., Lynn J., Zhong Z., Borum M., Dawson N.V. Dying with end stage liver disease with cirrhosis: insights from SUPPORT. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. J Am Geriatr Soc. 2000, 48:S122-S130.
16. Devulder J., Richarz U., Nataraja S.H. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin. 2005, 21:1555-1568.
17. Rhee C., Broadbent A.M. Palliation and liver failure: palliative medications dosage guidelines. J Palliat Med. 2007, 10:677-685.
18. Giovanni G., Giovanni P. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?. J Nephrol. 2002, 15:480-488.
19. Murray M.D., Brater D.C. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol. 1993, 33:435-465.
20. Benson G.D., Koff R.S., Tolman K.G. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther. 2005, 12:133-141.
21. Dart R.C., Kuffner E.K., Rumack B.H. Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. Am J Ther. 2000, 7:123-134.
22. Kuffner E.K., Green J.L., Bogdan G.M., et al. The effect of acetaminophen (four grams a day. BMC Med. 2007, 5:13.
23. Novick D.M., Kreek M.J., Fanizza A.M., Yancovitz S.R., Gelb A.M., Stenger R.J. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther. 1981, 30:353-362.
24. Tegeder I., Lotsch J., Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet. 1999, 37:17-40.
25. Marchesini G., Bianchi G., Amodio P., et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology. 2001, 120:170-178.
26. Lebovics E., Seif F., Kim D., et al. Pruritus in chronic hepatitis C: association with high serum bile acids, advanced pathology, and bile duct abnormalities. Dig Dis Sci. 1997, 42:1094-1099.
27. Kremer A.E., Beuers U., Oude-Elferink R.P., Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008, 68:2163-2182.
28. Bergasa N.V. Medical palliation of the jaundiced patient with pruritus. Gastroenterol Clin North Am. 2006, 35:113-123.
29. Mela M., Mancuso A., Burroughs A.K. Review article: pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther. 2003, 17:857-870.
30. Marzioni M., Svegliati Baroni G., Alpini G., Benedetti A. Endogenous opioid peptides and chronic liver disease: from bedside to bench. J Hepatol. 2007, 46:583-586.
31. Tandon P., Rowe B.H., Vandermeer B., Bain V.G. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol. 2007, 102:1528-1536.
32. Thornton J.R., Losowsky M.S. Opioid peptides and primary biliary cirrhosis. BMJ. 1988, 297:1501-1504.
33. Jones E.A., Neuberger J., Bergasa N.V. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM. 2002, 95:547-552.
34. Bergasa N.V., Schmitt J.M., Talbot T.L., et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology. 1998, 27:679-684.
35. Carson K.L., Tran T.T., Cotton P., Sharara A.I., Hunt C.M. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol. 1996, 91:1022-1023.
36. Dawn A.G., Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol. 2006, 54:527-531.
37. Runyon B.A. Treatment of patients with cirrhosis and ascites. Semin Liver Dis. 1997, 17:249-260.
38. Runyon B.A. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009, 49:2087-2107.
39. Santos J., Planas R., Pardo A., et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis: a randomized comparative study of efficacy and safety. J Hepatol. 2003, 39:187-192.
40. Gines P., Arroyo V., Quintero E., et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology. 1987, 93:234-241.
41. Salerno F., Badalamenti S., Incerti P., et al. Repeated paracentesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients: a safe alternative therapy. J Hepatol. 1987, 5:102-108.
42. Cardenas A., Gines P. Management of refractory ascites. Clin Gastroenterol Hepatol. 2005, 3:1187-1191.
43. Cardenas A., Gines P., Runyon B.A. Is albumin infusion necessary after large volume paracentesis?. Liver Int. 2009, 29:636-640. discussion 40-41.
44. Colombato L. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension. J Clin Gastroenterol. 2007, 41(suppl 3):S344-S351.
45. Campbell M.S., Brensinger C.M., Sanyal A.J., et al. Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology. 2005, 42:635-640.
46. Reisfield G.M., Wilson G.R. Management of intractable, cirrhotic ascites with an indwelling drainage catheter. J Palliat Med. 2003, 6:787-791.
47. Rosenblum D.I., Geisinger M.A., Newman J.S., et al. Use of subcutaneous venous access ports to treat refractory ascites. J Vasc Interv Radiol. 2001, 12:1343-1346.
48. Ferenci P., Lockwood A., Mullen K., Tarter R., Weissenborn K., Blei A.T. Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification-final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002, 35:716-721.
49. Das A., Dhiman R.K., Saraswat V.A., Verma M., Naik S.R. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol. 2001, 16:531-535.
50. Romero-Gomez M., Boza F., Garcia-Valdecasas M.S., Garcia E., Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001, 96:2718-2723.
51. Romero-Gomez M., Grande L., Camacho I. Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. Hepatology. 2004, 39:939-943.
52. Sundaram V., Shaikh O.S. Hepatic encephalopathy: pathophysiology and emerging therapies. Med Clin North Am. 2009, 93:819-836,. vii.
53. Morgan M.Y., Alonso M., Stanger L.C. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients: a randomised, cross-over study. J Hepatol. 1989, 8:208-217.
54. Atterbury C.E., Maddrey W.C., Conn H.O. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial. Am J Dig Dis. 1978, 23:398-406.
55. Lumby J. Liver transplantation: the death/life paradox. Int J Nurs Pract. 1997, 3:231-238.
56. van der Plas S.M., Hansen B.E., de Boer J.B., et al. Generic and disease-specific health related quality of life in non-cirrhotic, cirrhotic and transplanted liver patients: a cross-sectional study. BMC Gastroenterol. 2003, 3:33.
57. Laccetti M., Manes G., Uomo G., Lioniello M., Rabitti P.G., Balzano A. Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study. Dig Liver Dis. 2000, 32:335-338.
58. Pandharipande P., Shintani A., Peterson J., et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006, 104:21-26.
59. Nauck F., Alt-Epping B. Crises in palliative care: a comprehensive approach. Lancet Oncol. 2008, 9:1086-1091.
60. Monti M., Castellani L., Berlusconi A., Cunietti E. Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. J Pain Symptom Manage. 1996, 12:18-22.
61. Man-Son-Hing M., Wells G. Meta-analysis of efficacy of quinine for treatment of nocturnal leg cramps in elderly people. BMJ. 1995, 310:13-17.
62. Lee F.Y., Lee S.D., Tsai Y.T., et al. A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps. J Hepatol. 1991, 12:236-240.
63. Singh N., Gayowski T., Wagener M.M., Marino I.R. Depression in patients with cirrhosis. Impact on outcome. Dig Dis Sci. 1997, 42:1421-1427.
64. Kim S.H., Oh E.G., Lee W.H. Symptom experience, psychological distress, and quality of life in Korean patients with liver cirrhosis: a cross-sectional survey. Int J Nurs Stud. 2006, 43:1047-1056.. 134.